EHA: Cerdulatinib demonstrates rapid tumour responses in a phase 2 study for relapsed/refractory NHL
Cerdulatinib is an oral, dual Syk-JAK inhibitor with a unique mechanism of action. It inhibits…
Browsing: Cerdulatinib
Trending
- Making Telehealth Human – Podcast
- Sign Up for The Oncology Newsletter | Our free weekly news roundup
- The OJC Episode 22: Disparity Special
- Does aspirin lower colorectal cancer risk in older adults? It depends on when they start
- Pre-surgery chemotherapy is possible for early stage pancreatic cancer patients
- Better post-surgery care would dramatically improve cancer survival in LMICs
- Potential combined drug therapy for lung cancer
- Novel target: could improve safety of therapy for pancreatic cancer
- Team harvests cancer-killing exosomes from natural killer cells
- Study updates breast cancer risk estimates for women with no family history
